Month: March 2022

YAVNE, Israel, March 10, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2021 on Thursday, March 17 2022. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and to answer questions. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free: 877-602-7189Israel: 1-809-315-362International: 678-894-3057Conference ID: 2281543Webcast:  Click HERETo access the call, participants should dial the applicable...

First Step in Development Process of QRX003 for the EU ASHBURN, Va., March 10, 2022 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has submitted a Scientific Advice Briefing Document with the European Medicines Agency (EMA) for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure. The briefing document is intended to solicit feedback and guidance on the clinical and regulatory pathway for advancing QRX003 into clinical testing and subsequent potential marketing authorization submission and commercialization in the EU. “The...

CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that an interview with President and CEO Cuong Do will air on The RedChip Money Report® on Bloomberg TV, March 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States. The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years’ experience focused on Discovering Tomorrow’s Blue Chips Today™. “The RedChip Money Report®” delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as...

OTC:XCRT CEO Discusses Using AI to Advance Medical Care in Africa SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O’Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT), to discuss how the Company is utilizing artificial intelligence (AI) and other technologies to deliver healthcare to remote areas of Africa.AUSTIN, Texas, March 10, 2022 (GLOBE NEWSWIRE) — SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O’Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT), to discuss how the Company is utilizing artificial intelligence (AI) and other technologies to deliver healthcare to remote areas of Africa. Xcelerate is an innovation and development company that marries non-medical engineering, advancements and systems with MedTech and clinical care within the healthcare...

BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered antiviral CC-42344 for the treatment of pandemic and seasonal influenza A. The study is designed to assess the safety, tolerability and pharmacokinetics of CC-42344 with results expected later this year. The randomized, double-blind, placebo-controlled Phase 1 study is expected to enroll up to 56 healthy adults at a single site in Australia. CC-42344 is an oral PB2 inhibitor that blocks an essential step of influenza viral replication and transcription. CC-42344 was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. “There is an...

MELVILLE, N.Y., March 10, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a research collaboration agreement with Dr. Tore Bengtsson, Professor of the Department of Molecular Biosciences, at the Wenner-Gren Institute, at Stockholm University. The research is intended to advance the Company’s understanding of the biology and role of brown fat tissue in the ability to produce heat. The proposed research involves studying BioRestorative’s proprietary cell-lines, both primary adipose cells and brown adipocyte cells differentiated in culture, and their thermogenic response. “We are excited to enter into this research collaboration with Professor Bengtsson’s laboratory. Heat...

HERZLIYA, Israel and SAN FRANCISCO, March 10, 2022 (GLOBE NEWSWIRE) — Otonomo Technologies Ltd. (Otonomo), (Nasdaq: OTMO), the mobility intelligence company, today announced its participation in the upcoming Autonomy Paris show in Paris, France on March 16-17, 2022. Otonomo will be presenting its mobility intelligence solutions for urban planning, electric vehicle infrastructure and mobility services at Booth E5. Dan Elbaze, director, Sales & Business Development for Otonomo, will present “Three Solutions to Accelerate Your Smart City Strategy Today” at the show on March 16 at 10:25 a.m. on the London Stage. Mr. Elbaze will discuss how vehicle data and mobility intelligence combine to provide solutions to urban challenges. These solutions include reducing carbon emissions, supporting multi-modal transportation and planning...

SYDNEY, AUSTRALIA, March 10, 2022 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce it has received constructive feedback from the US Food and Drug Administration (FDA) regarding its clinical development program for lead product candidate, eftilagimod alpha (efti or IMP321), in metastatic breast cancer (MBC). In particular, the FDA has supported Immutep’s view to continue exploring the development of efti in MBC in a new registrational trial. The FDA’s feedback was based on clinical data presented by Immutep, including final overall survival data from its phase IIb AIPAC trial reported at the SITC 2021 conference (see announcements dated 10 and 15 November 2021). The advice from the FDA follows the receipt of feedback from the European Medicines Agency (EMA)...

Covering a full calendar year of activity post Reverse Merger with Duke RoboticsDuke Robotics Inc. developed TIKAD TIKAD, an advanced robotic system designed to serve the growing need for tech solutions in the combat fieldFort Lauderdale, Florida, March 10, 2022 (GLOBE NEWSWIRE) — UAS Drone Corp. (OTCQB: USDR), a leader in robotics technology and drone solutions, is pleased to announce the filing of its Annual Report, on Form 10-K for the 12 months ended December 31, 2021, with the U.S. Securities and Exchange Commission, covering a full calendar year of activity following the reverse merger between Duke Robotics, Inc. and the Company. Financial highlights:For the twelve months ended December 31, 2021, UAS Drone reported $500,000 in revenues from the Collaboration Agreement with Elbit Systems Land Ltd., a subsidiary of Elbit...

Cerence delivers completely voice-controlled karaoke experience designed specifically for drivers, powered by Stingray’s API technology and catalogue of more than 100,000 songs. VinFast signs on as first customer, integrating Cerence Sing into the VF 8 and VF 9.BURLINGTON, Mass., March 10, 2022 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced the introduction of Cerence Sing, powered by Stingray Karaoke, a completely voice-controlled karaoke experience designed specifically for the car that enables drivers and passengers to safely learn, practice and perform their favorite songs while on the go. In a strategic partnership, VinFast will be the first client to integrate Cerence Sing into its Smart Services on the VF 8 and VF 9, currently opened to global reservation....